MiR-155 inhibitors treat T-cell lymphoma and are designated by the FDA for orphan drugs.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The U.S. Food and Drug Administration (FDA) has awarded it the title of cobomarsen orphan drug for the treatment of T-cell lymphoma, the !---- biopharmaceutical company MiRagen Therapeutics announced.Cobomarsen, a miR-155 inhibitor developed by miRagen, is currently being developed in two clinical studies to treat different types of T-cell lymphoma, including Phase 2 clinical trials for skin T-cell lymphoma (CTCL) and Phase 1 clinical trials for adult T-cell leukemia/lymphoma (ATLL).found abnormally high levels of miR-155 in a variety of blood cancer cells. William S,, President and CEO of miRagen, said, "This is an important milestone in the development of cobomarsen, and we believe that cobomarsen has the potential to be used to treat other cancer patients with elevated miR-155." T-cell lymphoma (e.g. ATLL and CTCL) accounts for less than 15% of non-Hodgkin's lymphoma in the United States. there are many types of T-cell lymphoma in, but they are rare.the overexpression of microRNA-155 is associated with prognosis of multiple T-cell lymphomas and other blood cancers..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
